🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients

RecruitingPhase 2Ages 60 Years - anyAllGerman University in Cairo
NCT07338682 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the effect of L-arginine supplementation on cognitive function in geriatric patients. Eligible participants will receive either L-arginine (6 grams once daily) or placebo, and their cognitive performance will be assessed using validated cognitive assessment tools over the study period. The participants will receive the intervention for 4 weeks and followed up every 2 weeks. The primary outcome is improvement in cognitive function, while secondary outcomes include safety, tolerability, and quality of life measures. The findings may provide evidence for the potential role of L-arginine in supporting cognitive health in elderly populations.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age \>60 years * Montreal Cognitive Assessment (MoCA) test score from 10-25 (mild to moderate cognitive impairment) Exclusion Criteria: * Presence of neurodegenerative diseases (e.g.: Alzheimer's disease, Parkinson's disease, Huntington's disease, Multiple Sclerosis) * Patients with history of L-arginine intolerance or allergy * Patients with asthma * Patients who recently had an acute myocardial infarction * Patients with history of stroke within 1 yaear * Patients who started or discontinued medications that may affect cognitive function (e.g., CNS psychotropics, antihistamines, or acetylcholinesterase inhibitors) during the study period. * Patients who initiated or stopped antihypertensive medications during the study period. * Patients who initiated or stopped antidiabetic medications during the study period. * Patients who initiated or stopped antihyperlipidemic medications during the study period. * Patients prescribed medications for depression, anxiety, or stress that may impact cognitive function * Patients on nitrates, phosphodiesterase-5 inhibitors, potassium sparing diuretics * Refusal to provide written informed consent
💊

What it tests

  • L-Arginine
  • Placebo
📍

Where

1 site
Neurology Department, Al-Azhar University Hospitals
Cairo, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy